Fineline Cube

Follow:
14484 Articles
Novo Nordisk's Ozempic Receives Positive CHMP Opinion for Kidney Disease Indication
CompanyDrug

Novo Nordisk’s Ozempic Receives Positive CHMP Opinion for Kidney Disease Indication

Bayer AG Initiates Phase I Study Combining BAY3498264 with Sotorasib for KRAS-Mutated Tumors
CompanyDrug

Bayer AG Initiates Phase I Study Combining BAY3498264 with Sotorasib for KRAS-Mutated Tumors

CureGene Pharmaceutical Gets NMPA Approval for Antiplatelet Drug CG-0255
CompanyDrug

CureGene Pharmaceutical Gets NMPA Approval for Antiplatelet Drug CG-0255

Johnson & Johnson MedTech's Impella Heart Pumps Gain FDA Approval for Pediatric Heart Failure
CompanyMedical Device

Johnson & Johnson MedTech’s Impella Heart Pumps Gain FDA Approval for Pediatric Heart Failure

Pfizer's Ibrance Demonstrates Significant PFS Improvement in Phase III PATINA Trial
CompanyDrug

Pfizer’s Ibrance Demonstrates Significant PFS Improvement in Phase III PATINA Trial

BeiGene Ltd Acquires Global Rights to CSPC's MAT2A Inhibitor SYH2039
CompanyDeals

BeiGene Ltd Acquires Global Rights to CSPC’s MAT2A Inhibitor SYH2039

Gan & Lee Pharmaceuticals Gets FDA Approval for GZR18 Obesity/Overweight Phase II Study
CompanyDrug

Gan & Lee Pharmaceuticals Gets FDA Approval for GZR18 Obesity/Overweight Phase II Study

HutchMed's Orpathys Receives Breakthrough Therapy Designation in China for Advanced Lung Cancer
CompanyDrug

HutchMed’s Orpathys Receives Breakthrough Therapy Designation in China for Advanced Lung Cancer

HutchMed to Receive Milestone Payment as Takeda's Fruzaqla Gets Reimbursement Nod in Spain
CompanyDrug

HutchMed to Receive Milestone Payment as Takeda’s Fruzaqla Gets Reimbursement Nod in Spain

National VBP Program Round 10: 195 Manufacturers Secure Winning Bids for 62 Drugs
Policy / Regulatory

National VBP Program Round 10: 195 Manufacturers Secure Winning Bids for 62 Drugs

Grand Pharmaceutical Group Receives NMPA Approval for NOVASYNC HYBRID SYSTM
CompanyMedical Device

Grand Pharmaceutical Group Receives NMPA Approval for NOVASYNC HYBRID SYSTM

HuidaGene Therapeutics Launches MUSCLE Study for CRISPR Therapy in Duchenne Muscular Dystrophy
CompanyDrug

HuidaGene Therapeutics Launches MUSCLE Study for CRISPR Therapy in Duchenne Muscular Dystrophy